Idiopathic Pulmonary Fibrosis Treatment Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32

1
Global Idiopathic Pulmonary Fibrosis Treatment
Market Research and Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Idiopathic Pulmonary Fibrosis Treatment
  Market Global Industry Trends, Share, Size,
  Growth, Opportunity and Forecast
  2024-2032," the global idiopathic pulmonary
  fibrosis treatment market size reached US
  3,848.3 Million in 2023.
• Idiopathic pulmonary fibrosis (IPF) is an
  interstitial lung disease that causes scarring of
  the lungs, reducing their oxygen delivering
  capacity. The chronic lung disease is progressive
  and irreversible in nature as it continuously
  impacts the functioning of the lungs. It causes
  difficulty in breathing and does not provide
  sufficient oxygen to different body parts.
• IPF can be diagnosed through chest imaging
  studies, lung biopsies, pulmonary function tests,
  and antibody tests. The treatment includes
  nintedanib and pirfenidone-based drugs that aid
  in lung functioning and minimize the risk of
  acute respiratory deterioration. They are also
  offered along with oxygen therapy and palliative
  care, which improve the chances of recovery and
  provide comfort to the patient.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/idiopathic-pulmonary-fi
  brosis-treatment-market/requestsample

4
Report Description

• Global Idiopathic Pulmonary Fibrosis Treatment
  Market Trends
• The market is primarily driven by the rising
  geriatric population, which is susceptible to
  lung disorders. Aging is considered the greatest
  risk factor for the development of IPF. Moreover,
  the growing prevalence of fibrotic diseases,
  owing to changing lifestyles and heavy
  consumption of nicotine products like cigarettes
  is also propelling the demand for IPF treatment.
• Besides this, major healthcare companies are
  extensively investing in the development and
  commercialization of novel drugs, especially in
  emerging economies, which is fueling the growth
  of the market. The rising health consciousness
  among individuals regarding effective management
  strategies is also creating a positive outlook
  for the market. Furthermore, increasing
  healthcare expenditures and improving
  infrastructure are also facilitating the market
  growth.
• Looking forward, the market value is expected to
  reach US 6,980.4 Million by 2032, exhibiting a
  CAGR of 6.6 during the forecast period
  (2024-2032).
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/idiopathic-pulmonary-fi
  brosis-treatment-market

5
Report Segmentation

• Breakup by Drug Class
• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors
•  
• Breakup by End User
• Hospitals
• Long-term Care Facilities
• Others
• Breakup by Region
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

6
Competitive Landscape with Key Players

• AdAlta Pty Ltd.
• Angion Biomedica Corp.
• Boehringer Ingelheim International GmbH (C. H.
  Boehringer Sohn AG Co. KG)
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Fibrogen Inc.
• Galapagos NV
• Liminal BioSciences Inc.
• Medicinova Inc.
• Merck Co. Inc.
• Novartis AG
• Vectura Group Plc.

7
Key Questions Answered in the Report
8
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Idiopathic Pulmonary
  Fibrosis Treatment Market    5.1    Market
  Overview    5.2    Market Performance    5.3  
   Impact of COVID-19  5.4    Market Forecast
• 6     Market Breakup by Drug Class
• 6.1 MAPK Inhibitors
• 6.1.1 Market Trends
• 6.1.2 Market Forecast
• 6.2 Tyrosine Inhibitors
• 6.2.1 Market Trends
• 6.2.2 Market Forecast
• 6.3 Autotaxin Inhibitors
• 6.3.1 Market Trends
• 6.3.2 Market Forecast
• 7 Market Breakup by End User       

9
Table of Contents

• 7.1 Hospitals
• 7.1.1 Market Trends
• 7.1.2 Market Forecast
• 7.2 Long-term Care Facilities
• 7.2.1 Market Trends
• 7.2.2 Market Forecast
• 7.3 Others
• 7.3.1 Market Trends
• 7.3.2 Market Forecast
• 8 Market Breakup by Region
• 8.1 North America
• 8.1.1 United States
• 8.1.1.1 Market Trends
• 8.1.1.2 Market Forecast
• 8.1.2 Canada
• 8.1.2.1 Market Trends
• 8.1.2.2 Market Forecast
• 8.2 Asia Pacific
• 8.2.1 China

10
Partial List of Clients
11
Partial List of Clients
12
Disclaimer

• 2024 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

13
Contact Us
Visit us at
https//www.imarcgroup.com
1-631-791-1145
sales_at_imarcgroup.com
Stay With Us